Olymvax Biopharmaceuticals Inc. and Army Medical University Jointly Develop Coronavirus Disease (COVID-19) Vaccine
On February 12, 2020, Olymvax Biopharmaceuticals Inc. and the Army Military Medical University signed the joint development agreement on the “development of a new genetically engineered recombinant vaccine for COVID-19". The two parties will conduct research on the COVID-19 vaccine in their joint laboratory.
The research and development team under Professor Zou Quanming at the Army Military Medical University is responsible for the screening of immunogenic epitopes of the coronavirus, and constructing a vector to express immunogenic proteins. Pilot production of candidate protein antigens, quality studies and pharmacodynamic studies on animals will be completed by Olymvax’s R & D team.
By now, the research team has completed the construction of genetically engineered bacteria of key pathogenic protein antigens, ready to do animal experiments. At the same time, Olymvax is building a new workshop to satisfy the production. It is expected to complete the validation and will put into use in May.
Confronted with the serious epidemic, the development of a proventive vaccine is very urgent. The two parties will integrate their advantages, accelerate the development of the new coronavirus vaccine, hoping to get the vaccine launched as soon as possible.